Open AccessOral Selective Estrogen Receptor Degrader After Endocrine Therapy With a Cyclin-Dependent Kinase 4/6 Inhibitor
Author(s) -
Ryo Nishihara,
Akihiko Shimomura,
Chikako Shimizu
Publication year - 2022
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.22.01454
Subject(s) - medicine , palbociclib , estrogen receptor , fulvestrant , endocrine system , kinase , cancer research , oncology , cyclin dependent kinase 4 , estrogen , endocrinology , pharmacology , cancer , breast cancer , metastatic breast cancer , cyclin dependent kinase 2 , hormone , cell cycle , biochemistry , biology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom